GENET archive


8-Humans: Gene therapy using virus shows promise

genet-news mailing list

-------------------------------- GENET-news --------------------------------

TITLE:  Gene therapy using virus shows promise
SOURCE: Associated Press, by Paul Elias
DATE:   Jun 30, 2003

------------------ archive: ------------------

Gene therapy using virus shows promise 

SAN FRANCISCO - Scientists have worked for years to harness the power
that viruses have to invade cells, replacing unwanted elements of herpes
and other viruses with disease-fighting genes in hopes the new genetic
payload would correct a targeted illness.

Such genetic therapies have found limited success so far.

But a team of 12 Japanese and Belgian scientists says it has found
promise with the hepatitis B virus, using it as a tool to temporarily
treat hemophiliac mice.

The researchers reported Sunday in the online edition of the journal
Nature Biotechnology that their technique - using a small, hollow
fragment of the hepatitis B virus - enables the inserted genes to be more
narrowly focused than other viral delivery systems.

Engineered viruses sometimes deliver good genes to bad places, setting
unintended cellular changes in motion. That's what happened recently to
two boys who got leukemia after being successfully treated for the immune
disorder commonly called "bubble boy" disease.

Those other viruses have the potential of entering a wide variety of
cells, but the researchers said in their report that their hepatitis B
method targets only liver cells.

The researchers aren't using the whole hepatitis B virus, but instead are
inserting disease-fighting genes inside "nanoparticles," tiny fragments
of the virus.

Those nanoparticles dumped their genetic payload of blood-clotting genes
almost exclusively in the liver.

Using that technique, the researchers said, their test produced
measurable amounts of blood clotting proteins for about 40 days.

The nanoparticle is "a safe vehicle for delivering both genes and drugs,"
the researchers concluded. The lead author of the study was Tadanori
Yamada of Osaka University.

Gene therapy has been controversial since the 1999 death of 18-year-old
Jesse Gelsinger, who was given a different type of gene therapy for
another disease at the University of Pennsylvania in Philadelphia. He
developed an immune response to the virus being used.

French researchers rejuvenated the field last year when they reported
curing four boys of severe combined immunodeficiency, or SCIDs, and
better known as "bubble boy disease." But that excitement was tempered
months later because some of the inserted genes that cured the SCIDS also
ended up in the wrong place and caused two of the boys to develop leukemia.

The new technique may better protect against such unintended
consequences, the researchers said Sunday.

"Delivery is the big issue in gene therapy," said Dr. Mark Kay, director
of Stanford University's Human Gene Therapy Program." This is
encouraging. It's the kind of stuff we need in the field."

However, Kay said the latest work had limitations, highlighted by the
fact the gene therapy stopped working in the mice after a brief period.
Injecting more of the gene-carrying virus will cause the body to build up
resistance to the therapy, Kay said.

Another problem arises with the use of the hepatitis B virus because many
people are vaccinated against the disease, said gene therapy scientist
Inder Verma of the Salk Institute of Biological Studies. The vaccine will
kill the therapy as well, Verma said.

"It's exciting and interesting," Verma said. "But now what?"

Nature Biotechnology:
Kay's lab:
Verma's lab:


European NGO Network on Genetic Engineering

Hartmut MEYER (Mr)
Kleine Wiese 6
D - 38116 Braunschweig

phone:  +49-531-5168746
fax:    +49-531-5168747
mobile: +49-162-1054755
email:  genetnl(at)